v3.26.1
Balance Sheet Components - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 02, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Schedule of Available-for-sale Securities [Line Items]            
API and bulk drug product price true-up   $ 5,194,000   $ 5,194,000   $ 6,977,000
Available for sale investments contractual maturities       2 years    
Other impairment loss       $ 0 $ 0  
Credit related losses   $ 0 $ 0      
Closing of Divestiture of FibroGen International [Member]            
Schedule of Available-for-sale Securities [Line Items]            
Litigation settlement receivable           $ 4,000,000
Cash payments for restructuring $ 4,000,000